ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. Provision for income taxes

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥9.21T
P/E ratio
59.2x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProvision for income taxes (Million JPY)YoY (%)
Mar 31, 202566,941-173.23%
Mar 31, 2024-91,406-257.46%
Mar 31, 202358,052-19.82%
Mar 31, 202272,405-828.71%
Mar 31, 2021-9,936-90.54%
Mar 31, 2020-105,044+644.04%
Mar 31, 2019-14,118-121.53%
Mar 31, 201865,574+225.19%
Mar 31, 201720,165-22.72%
Mar 31, 201626,092-62.03%
Mar 31, 201568,717

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat